Abstract
The eye and the heart are two closely interlinked organs, and many diseases affecting the cardiovascular system manifest in the eye. To contribute to the understanding of blood flow propagation towards the retina, we developed a method to acquire electrocardiogram (ECG) coupled time-resolved dynamic optical coherence tomography (OCT) images. This method allows for continuous synchronised monitoring of the cardiac cycle and retinal blood flow dynamics. The dynamic OCT measurements were used to calculate time-resolved blood flow profiles using fringe washout analysis. The relative fringe washout was computed to generate the flow velocity profiles within arterioles at the optic nerve head rim. We found that the blood column between the heart and the retina propagates within one cardiac cycle, denoting the arrival time as the heart-retina time (HRT). In a group of healthy subjects, the HRT was 144 ± 19 ms (mean ± SD). The HRT could provide a novel potential biomarker for cardiovascular health in direct relation to retinal perfusion.
Competing Interest Statement
PV received speaker fees from Heidelberg Engineering GmbH and Bayer. HPNS is supported by the Swiss National Science Foundation (Project funding: 'Developing novel outcomes for clinical trials in Stargardt disease using structure/function relationship and deep learning' #310030_201165, and National Center of Competence in Research Molecular Systems Engineering: 'NCCR MSE: Molecular Systems Engineering (phase II)' #51NF40-182895, the Wellcome Trust (PINNACLE study), and the Foundation Fighting Blindness Clinical Research Institute (ProgStar study). Dr. Scholl is member of the Scientific Advisory Board of: Boehringer Ingelheim Pharma GmbH & Co; Droia NV; Eluminex Biosciences; Janssen Research & Development, LLC (Johnson & Johnson); Okuvision GmbH; ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc. Dr. Scholl is a consultant of: Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global, LLC; and Tenpoint Therapeutics. Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of Belite Bio (DRAGON trial, NCT05244304; LBS-008-CT02, NCT05266014), F. Hoffmann-La Roche Ltd (VELODROME trial, NCT04657289; DIAGRID trial, NCT05126966; HUTONG trial), ViGeneron (protocol number VG901-2021-A) and member of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561). PMM is a consultant of Roche and holds intellectual properties for machine learning at MIMO AG and VisionAI, Switzerland. The other authors declare no conflict. Funding organisations had no influence on the design, performance or evaluation of the current study.
Funding Statement
This study received funding via personal grants to PV from the Swiss National Science Foundation (Grant 323530_199395), AlumniMedizin Basel and the Janggen-Poehn Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Northwestern and Central Switzerland gave ethical approval for this work (EKNZ 2021-02360).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data presented in this paper are not publicly available due to data protection regulations. Interested parties may request access to the data from the corresponding author (PV) upon reasonable request and approval from the concerned institutional review boards.
